BIOMEDICINE versus TRADITIONAL MEDICINE. Therapy for HIV/AIDS. By: Nadia Chanzu, PhD Student, UNITID Infectious Minds Presentation 22 June 2011

Similar documents
BRIEF HISTORY WHY IK TANGA AIDS WORKING GROUP TANGA AIDS WORKING GROUP

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

Combating. Across Africa. and. Brain Wrinkles

The HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)

Assessment Schedule 2013 Health: Analyse an international health issue (91462)

Scaling up priority HIV/AIDS interventions in the health sector

HIV in Russia. Cost-effectiveness of Treating Injection Drug Users with Antiretroviral Therapy

UNRAVELING THE MYSTERY BEHIND HIV/AIDS

Health outcomes & research objectives in (crosscultural)international

Elaine Zuckerman Embassy of the Republic of Zambia December 1, 2009

ART for prevention the task ahead

RAPID DIAGNOSIS AND TREATMENT OF MDR-TB

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN

African Traditional Medicine

Millennium Development Goals: At a Glance

United Nations General Assembly June 8, 2011

PROJECT: APPLYING ADVANCED ANALYTICS TO HELP IMPROVE MENTAL HEALTH AMONG HIV POSITIVE ADOLESCENTS IN SOUTH AFRICA

Since the start t of the HIV/ 1980 s: 77.3 million people have be. In million people were liv

Housing / Lack of Housing and HIV Prevention and Care

A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2

Microchip Technology. Xuanhong Cheng Materials Science and Engineering

Page 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions

SPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA. 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m.

The Struggle with Infectious Disease. Lecture 6

Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014

TB/HIV Monitoring & Advocacy Project Interview Tool

AIDS in Africa. An Update. Basil Reekie

Trends in HIV/AIDS epidemic in Asia, and its challenge. Taro Yamamoto Institute of Tropical Medicine Nagasaki University

UNAIDS 2013 AIDS by the numbers

The Global Fund & UNICEF Partnership

HIV and Paediatrics in Central Europe

Renewing Momentum in the fight against HIV/AIDS

Improving accessibility to antiretroviral drugs: A south-south collaboration

INTERNAL QUESTIONS AND ANSWERS DRAFT

GLOBAL STATISTICS FACT SHEET 2015

Why should AIDS be part of the Africa Development Agenda?

IJMSS Vol.04 Issue-04 (April, 2016) ISSN: International Journal in Management and Social Science (Impact Factor )

Funding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia

Complementary Interventions (CIV) HIV Reporting FY12 Q2

Ending The HIV/AIDS Epidemic in America

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence

7.5 South-East Asian Region: summary of planned activities, impact and costs

Access to reproductive health care global significance and conceptual challenges

Okinawa, Toyako, and Beyond: Progress on Health and Development

PROMOTING GENDER RESPONSIVE & INCLUSIVE TRANSPORT PROJECTS

Submitted electronically to:

Latest Funding Trends in AIDS Response

Anti Retroviral Traitment (ARVs)

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016

Educational Challenges in Building the Health Infrastructure to Combat HIV/AIDS

International Journal of Pharma and Bio Sciences V1(2)2010 A STUDY ON PRESCRIPTION PATTERN AND COST ANALYSIS OF ANTIRETROVIRAL DRUGS.

Six things you need to know

Recipients of development assistance for health

Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation

Progress against the HIV Epidemic: is the end in sight?

Partners for Health Reformplus. Strengthening Health System Responses to HIV/AIDS

Lecture Outline: HIV/AIDS in. Africa

5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1

Module 1: HIV epidemiology, transmission and prevention

Addressing climate change driven health challenges in Africa

Agenda Part I: Overview of implementation of POC technologies Global Pan Canadian Regional-Quebec Part II: In-view CIHR funded Evidence syntheses HIV

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs

A Global Strategy Framework. Prepared by the UNAIDS Inter-Agency Working Group on. HIV/AIDS, Schools and Education

26 th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland June 2010

Richard A. Jenkins PhD Prevention Research Branch, NIDA July 19, 2017 Fordham University

HIV/AIDS in East Asia

Cross-Border Cooperation in the Global Fight against Communicable Diseases

2013 progress report on the Global Plan

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

ViiV Healthcare s Position on Prevention in HIV

Swaziland Government, HIV/AIDS Crisis Management and Technical Committee Swaziland National Strategic Plan for HIV/AIDS

IMPACT OF DEVELOPMENT ASSISTANCE FOR HEALTH ON COUNTRY SPENDING

Health Task Force Workplan

Towards universal access

HIV Vaccine Clinical Trials at CIDRZ

8/10/2015. Introduction: HIV. Introduction: Medical geography

Mission, Values and Vision. 1. To promote a long, joyous, healthier life and to provide affordable, compassionate holistic medical care for islanders.

High Level Regional Consultation for Policy Makers to Enhance Leadership in Planning the National HIV & AIDS Response. HIV Prevention (PM1S4)

The road towards universal access

Global and National trends of HIV/AIDS

Program to control HIV/AIDS

FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030

Evolving Realities of HIV Treatment in Resource-limited Settings

Structural barriers to highly active antiretroviral therapy (HAART) adherence: a systematic review protocol

ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV

Strategic Plan. Briefing. Strategic Plan Annual Results. Briefing. Associate Director, Nutrition 15 June 2015 Danny Kaye. Associate Director

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

Index. Nurs Clin N Am 41 (2006) Note: Page numbers of article titles are in boldface type.

Q&A on HIV/AIDS estimates

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

Good Health & Well-Being. By Alexandra Russo

Sysmex Educational Enhancement and Development No

XIV INTERNATIONAL CONFERENCE PERSON LIVING WITH HIV IN FAMILY AND SOCIETY. Warsaw, Poland. 28 November 2007

Antimicrobial resistance Fact sheet N 194 Updated April 2014

HIV Drug Resistance South Africa, How to address the increasing need? 14 Apr. 2016

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

90% 90% 90% 30% 10% 5% 70% 90% 95% WHY HIV SELF-TESTING? PLHIV diagnosed PLHIV undiagnosed

Peace Corps Global HIV/AIDS Strategy (FY )

the Office of Research Application Portal: Materials to submit:

Transcription:

BIOMEDICINE versus TRADITIONAL MEDICINE Therapy for HIV/AIDS By: Nadia Chanzu, PhD Student, UNITID Infectious Minds Presentation 22 June 2011

BIOMEDICINE Therapy for HIV/AIDS

Anti-Retroviral Therapy Highly active anti-retroviral therapy (HAART) is the current HIV/AIDS treatment modality Very effective in suppressing HIV-1 replication and reducing the mortality of HIV/AIDS patients The primary targets for anti-hiv-1 therapeutic development are two virally encoded enzymes: Reverse Transcriptase (RT) and Protease (PR)

Image edited from www.medscape.com

The Food and Drug Administration (FDA) has approved over 20 anti-hiv-1 drugs majority are HIV-1 RT and PR inhibitors Various combinations of these inhibitors, socalled highly active anti-retroviral therapy (HAART) potent, convenient and usually well tolerated capable of reducing HIV blood concentration to undetectable values within a few weeks inducing a robust and sustained CD4 T-cell gain

However, the current treatments used are: unable to eradicate HIV from infected individuals therapy must be lifelong potential for side effects pathogenesis of unexpected systemic complications owing to chronic inflammation & immune dysfunction associated to HIV infection life expectancy of people under ARV therapy remains lower with respect to that of uninfected people high costs for health care system

Bigger Picture! Dis-homogenous pattern of HIV disease worldwide (70% of the burden in Africa!) Access to HIV diagnosis, treatment and care are seriously limited in the geographical areas that are most affected Undiagnosed and untreated population represents an infected reservoir that increases HIV transmission

TRADITIONAL THERAPEUTIC OPTIONS Two Examples CHINA (Basic Science) TANZANIA (Social Science)

EAST ASIA China Relatively fewer anti-hiv-1 therapeutics have been developed to target other steps of HIV-1 life cycle including entry, fusion, and integration (In-Woo Park et al. 2009)

A panel of traditional Chinese medicinal herbal extracts obtained from plants in Hainan Island, China Extracts from Euphorbiaceae, Trigonostema xyphophylloides (TXE) and Dipterocarpaceae, Vatica astrotricha (VAD) both block HIV-1 replication at the entry step Potential of developing these plant extracts as anti-hiv-1 entry inhibitors

Extracts from the stem of TXE and the stem of VAD: Inhibited HIV-1 replication without apparent effects on cell proliferation and cell survival Prevented HIV-infected cells from forming syncytia Potently blocked HIV-1 from entering its target cells Had little effects on post-entry HIV-1 gene expression

TXE and VAD extracts possess potent inhibitory activities against HIV-1 replication and entry of both T and M tropic HIV-1 isolates These results suggest that TXE and VAD are potential biosources for further identification and isolation of active anti-hiv-1 constituents Identification of these active constituents will help establish the precise mechanisms of this entry inhibition as well as standardize the extracts for potential clinical translation

SUB-SAHARAN AFRICA Tanzania As in most parts of Africa, traditional medicine remains a relatively untapped resource in the overall struggle against AIDS (Kisangau D. et al. 2011)

HIV/AIDS pandemic: currently the largest socio-economic challenge that faces Tanzania Traditional medicines are the most widely established and available health care system: > 60% of the population depends on traditional medicines The ratio of Medical Doctors to traditional healers in Tanzania is estimated at 1:350

Community Based Initiative Tanga AIDS Working Group (TAWG) Traditional Medical Island of Hope Build capacity of traditional healers Provide effective low cost herbal remedies Research on promising herbs Ensure sustainable supply of medicinal plants Treated 4,500 AIDS patients with opportunistic infection; currently over 1300 patients

Efforts are underway to scale up TAWG s experience to other parts of Tanzania and possibly other regions of Africa The World Bank Indigenous Knowledge for Development Program: supported a community-to-community exchange of experiences between healers, people living with AIDS and staff working with patients with similar communities across the country.

Institution Based Initiative Gaps exist between THs and biomedical scientists in health research Recognition of THs as stipulated: National Health Policy, the Policy and Act of Traditional, complementary and alternative medicine The priority institution: The Institute of Traditional Medicine (ITM), Started in 1974, Today A Centre of Excellence!

CONCLUSION Leveraging traditional and modern knowledge systems to help combat HIV/AIDS

HIV is now a chronic illness in patients with continued treatment access and excellent long-term adherence Huge efforts are ongoing to reproduce these results even in poor and disadvantaged settings All currently FDA-approved anti-hiv drugs are chemically synthesized

Development involves an extremely long cycle of research, design and optimization, thus these drugs are very expensive Use is often limited by side- effects and nonadherence issues In contrast, medicines of natural origins such as herbs have a much short development cycle and relatively inexpensive

Importantly, the toxicity of nature-derived medications is rarely an issue (mainly address opportunistic infections) There is need to further investigate and develop alternative anti-hiv therapy ultimately affordable and available to all HIV/AIDS- affected individuals including those in developing and under-developed countries

RECOMMENDATIONS! It is crucial to bridge the yawning gap between traditional and modern health sectors

Community seminars should be conducted Exchange knowledge around themes associated with HIV/AIDS to improve the skills and knowledge base of all concerned Sub-communities representing: Traditional Healers Care givers / Social Scientists Medical Doctors / Research Scientists People living with HIV or AIDS, PLWHA

The Indigenous Knowledge Program has also helped incorporate the TAWG model into the World Bank supported Multi-country HIV/AIDS Program for Africa (MAP) In countries such Guinea, Ghana, Ethiopia and Burundi, traditional healers are being incorporated into national AIDS programs that have a country wide impact

THANK YOU!

References In-Woo P, Changri H, Xiaoping S et al. (2009). Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. BMC Complementary and Alternative Medicine, 9: 29. Kisangau DP, Herrmann TM, Lyaruu HVM et al. (2011). Traditional Knowledge, Use Practices and Conservation of Medicinal Pl ants for HIV/AIDS Care in Rural Tanzania. Ethnobotany Research & Applications, 9, p.43 57 Bodeker G, Carter G Durford G and Dvorak-Little M. (2006) HIV/AIDS: Traditional Systems of Health Care in the Management of a Global Epidemic. The Journal of Alternative and Complementary Medicine, 12 (6), p. 563 576 Lucia P and Stefano V. (2011). A brief history of antiretroviral therapy of HIV infection: success and challenges. New Challenges in Translational Medicine, 47 (1), p. 44-48